Literature DB >> 21838433

Antisense oligonucleotide therapy for TTR amyloidosis.

M D Benson1, S Pandey, D Witchell, A Jazayeri, A Siwkowski, B Monia, B Kluve-Beckerman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21838433     DOI: 10.3109/13506129.2011.574354021

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


× No keyword cloud information.
  10 in total

Review 1.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

Review 2.  Long non-coding RNAs in immune regulation and their potential as therapeutic targets.

Authors:  Dinesh Babu Uthaya Kumar; Adam Williams
Journal:  Int Immunopharmacol       Date:  2020-02-12       Impact factor: 4.932

Review 3.  Newer Therapies for Amyloid Cardiomyopathy.

Authors:  Rajshekhar Chakraborty; Eli Muchtar; Morie A Gertz
Journal:  Curr Heart Fail Rep       Date:  2016-10

Review 4.  Nuclear imaging modalities for cardiac amyloidosis.

Authors:  Sabahat Bokhari; Reehan Shahzad; Adam Castaño; Mathew S Maurer
Journal:  J Nucl Cardiol       Date:  2014-02       Impact factor: 5.952

Review 5.  Cardiac Amyloidosis and its New Clinical Phenotype: Heart Failure with Preserved Ejection Fraction.

Authors:  Evandro Tinoco Mesquita; Antonio José Lagoeiro Jorge; Celso Vale Souza; Thais Ribeiro de Andrade
Journal:  Arq Bras Cardiol       Date:  2017-06-29       Impact factor: 2.000

6.  Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study.

Authors:  Lawreen H Connors; Flora Sam; Martha Skinner; Francesco Salinaro; Fangui Sun; Frederick L Ruberg; John L Berk; David C Seldin
Journal:  Circulation       Date:  2015-12-11       Impact factor: 29.690

Review 7.  Recent Advances in Cardiovascular Imaging Relevant to the Management of Patients with Suspected Cardiac Amyloidosis.

Authors:  James A White; Nowell M Fine
Journal:  Curr Cardiol Rep       Date:  2016-08       Impact factor: 2.931

Review 8.  Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis.

Authors:  Veena Mathew; Annabel K Wang
Journal:  Drug Des Devel Ther       Date:  2019-05-06       Impact factor: 4.162

9.  Steric Inhibition of 5' UTR Regulatory Elements Results in Upregulation of Human CFTR.

Authors:  Shruti Sasaki; Rachel Sun; Huynh-Hoa Bui; Jeff R Crosby; Brett P Monia; Shuling Guo
Journal:  Mol Ther       Date:  2019-07-12       Impact factor: 11.454

10.  99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis: Potential clinical implications.

Authors:  Joohee Lee; Kihyun Kim; Jin-Oh Choi; Seok Jin Kim; Eun-Seok Jeon; Joon Young Choi
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.